Abstract:Brain metastases (BM), with a dismal prognosis, are a common and lethal complication of non-small cell lung cancer. Approximately, 10% patients present with BM at their initial diagnosis. Although, surgery and/or radiation therapy remain to be the mainstay treatment, targeted therapies are finding increasing application in treating BM. However, due to the very limited accessibility of brain lesions, its genomic and epigenomic landscape remain elusive. Capture-based targeted sequencing for somatic mutation profiling was performed on 27 treatment-naïve advanced NSCLC patients with paired lung primary and BM lesions using a pane consisting of 520 cancer related genes. DNA methylation analyses was performed on same samples using a DNA methylation panel consisting of 100,000 CpG sites. Collectively, we identified 370 (291 SNVs+Indels, 78 CNVs and 1 rearrangement) and 574 (245 SNVs+Indels, 327 CNVs and 2 rearrangements) mutations from lung primary lesions and BM, respectively. Among them, 242 mutations were shared; 128 were lung primary-specific and 332 were BM-specific. Among the BM specific mutations, a majority of them (82%, 272/332) were copy number variations (CNVs). Only 16% of CNVs were shared by lung lesions and BM. The concordance for SNVs and indels were much higher-54% between the two sources of tissues. Furthermore, we observed a much higher concordance rate (79%) in TP53 and classic lung cancer driver genes than other genes (p<0.001), indicating that they might be stem mutations. Next, we performed pathway analysis of genes that were only mutated in BM and revealed an enrichment of genes participating in PI3K-AKT and focal adhesion pathways. We also compared tumor mutation burden (TMB) between them and revealed comparable TMB (p=0.1). Our DNA methylation analysis revealed distinct methylation patterns with 268 blocks that are significantly differentially methylated between primary lung lesions and BM. Among them, 211 blocks were hypermethylated in BM and the remaining 57 blocks were hypermethylated in lung lesions. These blocks were enrichment in genes participating in cell adhesion, Rap1 signaling and calcium signaling pathways. We revealed diverse somatic mutation and DNA methylation profiles between lung primary lesions and BM. BM had significantly more unique CNVs. A great concordance was observed for classic lung cancer driver genes and TP53. Our study provided a comprehensive view of genomic and DNA methylation profiling for lung primary lesions and BM, paving the avenue for the development of targeted therapies for treating BM.

Methylation Signature of Lymph Node Metastases in Breast Cancer Patients.

P1.01-18 Integrated Genomic and DNA Methylation Analyses of Non-Small Cell Lung Cancer Patients with Brain Metastases

Tumor Suppressor Genes Are Frequently Methylated in Lymph Node Metastases of Breast Cancers

Methylation Profiles of 22 Candidate Genes in Breast Cancer Using High-Throughput MALDI-TOF Mass Array

A DNA Methylation-based Epigenetic Signature for the Identification of Lymph Node Metastasis in T1 Colorectal Cancer

Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients

Aberrant Promoter Methylation of Cancer-Related Genes in Human Breast Cancer

Detection of Aberrantly Methylated Tumor Suppressor Genes in Breast Cancer Patients As a Potential Diagnostic Biomarker

Integrated analysis of gene expression and methylation profiles of 48 candidate genes in breast cancer patients

Genetic methylation and lymphoid malignancies: biomarkers of tumor progression and targeted therapy

Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer

A novel DNA methylation signature associated with lymph node metastasis status in early gastric cancer

Detection of BRCA1,CDH1,DKK1 and SFRP1 Methylation in Peripheral Blood Cells of Patients with Metastatic Breast Cancer

A Six-Gene Signature Related with Tumor Mutation Burden for Predicting Lymph Node Metastasis in Breast Cancer

Running title : Metastasis signature Methylation Signature of Lymph Node Metastases in Breast Cancer Patients

DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells

Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer

Analysis of N6-Methyladenosine Methyltransferase Reveals METTL14 and ZC3H13 as Tumor Suppressor Genes in Breast Cancer

Identification of molecular markers for metastasis-related genes in primary breast cancer cells

Hypermethylation of Tumor Suppressor Genes Involved in Critical Regulatory Pathways for Developing A Blood-Based Test in Breast Cancer